Kyowa Hakko President Sets Goals To Overtake Genentech
This article was originally published in PharmAsia News
Executive Summary
At a Tokyo press briefing, Kyowa Hakko President Yuzuru Matsuda disclosed that he and John Maraganore, CEO of American company Alnylam Pharmaceuticals, had made a bet to see which company would first overtake Genentech. Matsuda also stated that Kyowa will be able to achieve similar growth enjoyed by Genentech and Amgen if it utilizes its advantage in antibody technology. Commenting on RNAi drug development, in which Kyowa and Alnylam formed an exclusive alliance to develop and commercialize the RNAi therapeutic drug ALN-RSV01, Matsuda said Kyowa has to keep a venture enterprise spirit and develop two fronts in both antibody and RNAi. (Click here for more - Japanese language